Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maxime Dube"'
Autor:
George G. Zhanel, Rita Dhami, Melanie Baxter, Justin Kosar, Carlos Cervera, Neal Irfan, Rosemary Zvonar, Sergio Borgia, Jean-Francois Tessier, Gordon Dow, Robert Ariano, Maxime Dube, Michel Savoie, Matteo Bassetti, Andrew Walkty, James A. Karlowsky
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 25, Iss , Pp 346-350 (2021)
ABSTRACT: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR r
Externí odkaz:
https://doaj.org/article/2b4678c622d745ac8f412da2da45c1cb
Autor:
George G. Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Kelly S. MacDonald, Gordon Dow, Philippe Lagacé-Wiens, Maxime Dube, Marco Bergevin, Carlo Tascini, Yoav Keynan, Andrew Walkty, James Karlowsky
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 335-339 (2021)
Objectives: Ceftobiprole is an advanced-generation cephalosporin with a favourable safety profile. Published data on the clinical use of ceftobiprole are limited. We report use of ceftobiprole in Canadian patients using data captured by the CLEAR reg
Externí odkaz:
https://doaj.org/article/280243864b9146c38bb05f49667fa5e1
Autor:
Maxime Dube, Sergio Borgia, James A. Karlowsky, Andrew Walkty, Jean-Francois Tessier, Michel Savoie, Robert E. Ariano, Gordon Dow, Rita Dhami, Melanie R. Baxter, Carlos Cervera, Matteo Bassetti, Rosemary Zvonar, Neal Irfan, George G. Zhanel, Justin Kosar
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 25, Iss, Pp 346-350 (2021)
Objectives Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. We report the use of ceftolozane/tazobactam in Canada using a national registry. Methods The CLEAR registry uses REDC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc3e62b0fff236ef1c4722e33ac42767
https://doi.org/10.1016/j.jgar.2021.03.025
https://doi.org/10.1016/j.jgar.2021.03.025
Autor:
James A. Karlowsky, Marco Bergevin, Andrew Walkty, Sergio Borgia, Yoav Keynan, Neal Irfan, Rita Dhami, Melanie R. Baxter, George G. Zhanel, Maxime Dube, Justin Kosar, Carlo Tascini, Gordon Dow, Philippe Lagacé-Wiens, Kelly MacDonald
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss, Pp 335-339 (2021)
Objectives Ceftobiprole is an advanced-generation cephalosporin with a favourable safety profile. Published data on the clinical use of ceftobiprole are limited. We report use of ceftobiprole in Canadian patients using data captured by the CLEAR regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b486d421af9d50b7c0914bd13cdc2e3c
https://doi.org/10.1016/j.jgar.2021.01.014
https://doi.org/10.1016/j.jgar.2021.01.014